Cytek Biosciences Inc
NASDAQ:CTKB
Cytek Biosciences Inc
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
Record Revenue: Cytek delivered its highest-ever quarterly revenue in Q4 2025 at $62.1 million, up 8% year-over-year and in line with expectations.
Growth Drivers: Revenue growth was driven by a rebound in EMEA, continued strength in APAC, and stabilization in the U.S., especially among academic and government customers.
Recurring Revenue: Recurring revenue reached 34% of total revenue in 2025, growing 21% year-over-year, with strong contributions from service and reagents.
Margins Under Pressure: Gross margins declined due to higher costs, tariffs, and manufacturing overhead from transitioning production, resulting in a Q4 net loss of $44.1 million (including a large non-cash tax valuation allowance).
2026 Outlook: Management guided 2026 revenue to $205–212 million, implying 2–5% growth and continued positive adjusted EBITDA, reflecting a cautious but stable market outlook.
Investments & Innovation: The company expanded its instrument base (up 22% in 2025), launched successful new products, and invested in manufacturing and sales teams to support future growth.
